Innovations in chemotherapy for metastatic colorectal cancer: An update of recent clinical trials

Oncologist

Volumn 13, Issue 10, 2008, Pages 1074-1083

  O'Neil, Bert H ^a,b   Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Biologic therapy; Chemotherapy; Colorectal cancer; Metastatic

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVOFOLINATE; OXALI; OXALIPLATIN; PANITUMUMAB; PLACEBO; UNCLASSIFIED DRUG;

ADD ON THERAPY; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LOADING DRUG DOSE; MAINTENANCE THERAPY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; ONCOGENE K RAS; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 55049130752     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0083     Document Type: Review

References (48)

1. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2004/, accessed November 15, 2007.
2. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047. Erratum in: Lancet 2000;355:1372.
4. Kohne CH, Van Cutsem E, Wils JA et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003;22:1018.
5. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
6. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:512.
7. Hedrick E, Kozloff M, Hainsworth J et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006;24(18 suppl):3536.
8. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
9. Sanoff HK, Sargent DJ, Campbell ME et al. N9741: Survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(18 suppl):4067.
10. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-237.
11. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
12. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2006;24(18 suppl):3510.
13. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. The Oncologist 2007;12:38-50.
14. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
15. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 2007;25(18 suppl):4028.
16. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987-989.
17. Fuchs CS, Marshall J, Mitchell EP et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: Updated efficacy data. J Clin Oncol 2007;25(18 suppl):4027.
18. André T, Tabernero J, Van Cutsem E et al. Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Final results. Presented at the 2007 Gastrointestinal Cancers Symposium, Orlando, FL, January, 2007.
19. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007;25(18 suppl):4000.
20. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J Clin Oncol 2006;24(18 suppl):3509.
21. ClinicalTrials.gov. Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00265850?order=1, accessed July 26, 2007.
22. Hecht JR, Mitchell E, Chidiac T et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
23. Hecht JR, Chidiac T, Mitchell E et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (bev) for metastatic colorectal cancer (mCRC). Presented at the 2007 World Gastrointestinal Cancer Congress Meeting, Barcelona Spain, June 2008.
24. Sobrero AF, Fehrenbacher L, Rivera F et al. Randomized Phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: The EPIC trial. Presented at the 2007 American Association of Cancer Research Annual Meeting, Los Angeles, CA, April 14-18, 2007.
25. Eng C, Maurel J, Scheithauer W et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol 2007;25(18 suppl):4003.
26. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
27. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66: 3992-3995.
28. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
29. Grothey A, Sugrue M, Hedrick E et al. Association between exposure to bevacizumab (BV) beyond first progression (BFP) and OS (OS) in patients (pts) with metastatic colorectal cancer (mCRC). Results from a large observational study (BRiTE). J Clin Oncol 2007;25(18 suppl):4036.
30. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
31. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24:394-400.
32. Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (mCRC): A GERCOR study. J Clin Oncol 2007;25(18 suppl):4013.
33. ClinicalTrials.gov. CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00129870?order=3, accessed February 8, 2007.
34. Hochester HS, Grothey A, Shpilsky A et al. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Presented at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
35. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007;25:4028-4029.
36. Labianca R, Floriani I, Cortesi E et al. Italian Group for the Study of Digestive Tract Can. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial. J Clin Oncol 2006;24(18 suppl):3505.
37. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 2007;370:135-142.
38. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomized controlled trial. Lancet 2007;370:143-152.
39. Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007;25(18 suppl):LBA5.
40. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver metastases]. Ann Surg Oncol 2001;8:347-353.
41. Adam R. Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14(suppl 2):ii13-ii16.
42. Perez-Staub N, Lledo G, Paye F et al. Surgery of colorectal metastasis in the OPTIMOX1 study. A GERCOR Study. J Clin Oncol 2006;24(18 suppl):3522.
43. Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9249.
44. Nordlinger B, Brouquet A, Penna C et al. Complete radiological response of colorectal liver metastases (LM) after chemotherapy: Does it mean cure? J Clin Oncol 2006;24(18 suppl):3501.
45. Gruenberger T, Sorbye H, Debois M et al. Tumor response to pre-operative chemotherapy (CT) with FOLFOX4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. J Clin Oncol 2006;24(18 suppl):3500.
46. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-1676.
47. Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805.
48. Adam R, Aloia T, Lévi F et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007;25:4593-4602.